Citron Updates GBTC – What Investors NEED to Know

, , ,

Last week, Citron Research put out a tweet about the Grayscale Bitcoin Investment Trust (OTCMKTS:GBTC) that discussed its net asset value/share price. We believe it is important to clarify this point, and at the same time, illustrate more risks in owning this trust. As of the writing of this article, here is what the math behind GBTC looks like:

Motorola Solutions – Total Eclipse of the Truth

, , ,

Investors who choose to believe in the false statements from Motorola Solutions can be as blinded as those who choose to stare at a solar eclipse.

Motorola Solutions (NYSE:MSI) is on the wrong side of a mega-trend (LMR to LTE)
The effects of FirstNet will weaken Motorola pricing power
70%+ of the company’s EBITDA is monopoly priced handsets; increased discounting emerges

FDA FAERS Database Posts Huge Rise in Acthar Deaths and Adverse Events

, , ,

IT’S TIME TO END THIS DANGEROUS GAME OF GREED NOW!

As if last month’s comments from Express Scripts were not bad enough for Mallinckrodt … The FDA has just disclosed information that could lead to criminal prosecution of Mallinckrodt executives. Three weeks ago, Express Scripts, the PBM whose subsidiaries are responsible for executing the entire delivery chain for Mallinckrodt’s Acthar, made a group of damning statements: that Acthar was an old drug, grossly overpriced, with very limited patient need, and was being used for label indications for which there was no clinical evidence.

THIS JUST GOT MUCH MORE SERIOUS THAN PROFITS